Merit Medical Sales Surge 12% to $1.12B, Net Income Dips Slightly

Ticker: MMSI · Form: 10-Q · Filed: Oct 30, 2025 · CIK: 856982

Merit Medical Systems Inc 10-Q Filing Summary
FieldDetail
CompanyMerit Medical Systems Inc (MMSI)
Form Type10-Q
Filed DateOct 30, 2025
Risk Levelmedium
Pages14
Reading Time17 min
Sentimentmixed

Sentiment: mixed

Topics: Medical Devices, Earnings Report, Revenue Growth, Net Income Decline, Acquisition, Operating Expenses, Shareholder Equity

Related Tickers: MMSI

TL;DR

**MMSI's sales are up, but net income is down – watch those margins, traders!**

AI Summary

MERIT MEDICAL SYSTEMS INC (MMSI) reported a robust financial performance for the nine months ended September 30, 2025, with net sales increasing by 12.05% to $1.12 billion from $1.00 billion in the prior year. Gross profit also saw a significant rise of 15.43% to $542.9 million, up from $470.35 million. Despite these gains, net income slightly decreased by 2.08% to $90.48 million from $92.41 million, primarily due to higher operating expenses, which climbed 17.41% to $412.39 million. Research and development expenses increased by 13.71% to $70.81 million, reflecting continued investment in innovation. The company's cash and cash equivalents grew to $392.46 million as of September 30, 2025, from $376.72 million at December 31, 2024. A key strategic move was the acquisition of Biolife on May 16, 2025, indicating expansion efforts. Diluted earnings per common share decreased to $1.49 from $1.57, influenced by the slight dip in net income and an increase in weighted average diluted shares outstanding to 60.60 million. Total assets expanded by 8.78% to $2.63 billion from $2.42 billion, driven by increases in property and equipment and intangible assets.

Why It Matters

This 10-Q reveals MMSI's strong top-line growth, indicating healthy demand for its medical products, which is positive for investors. However, the slight dip in net income despite higher sales suggests margin pressures or increased investment, impacting profitability. The acquisition of Biolife signals strategic expansion, potentially broadening its market reach and competitive edge against rivals like Boston Scientific or Medtronic. For employees, this growth could mean job security and opportunities, while customers benefit from continued product innovation. The broader market will watch how MMSI balances growth with profitability in a competitive medical device landscape.

Risk Assessment

Risk Level: medium — The company's net income decreased by 2.08% to $90.48 million for the nine months ended September 30, 2025, despite a 12.05% increase in net sales, indicating potential margin compression or increased operational costs. Additionally, total operating expenses rose by 17.41% to $412.39 million, outpacing revenue growth and posing a risk to future profitability if not managed effectively.

Analyst Insight

Investors should closely monitor MMSI's upcoming earnings calls for management's explanation of the net income decline and strategies to improve profitability. While sales growth is strong, the increase in operating expenses and slight dip in net income warrant caution; consider holding rather than buying aggressively until margin trends clarify.

Financial Highlights

debt To Equity
0.72
revenue
$1.12B
total Assets
$2.63B
total Debt
$732.92M
net Income
$90.48M
eps
$1.49
gross Margin
48.47%
cash Position
$392.46M
revenue Growth
+12.05%

Key Numbers

  • $1.12B — Net Sales (Increased by 12.05% for the nine months ended September 30, 2025)
  • $90.48M — Net Income (Decreased by 2.08% for the nine months ended September 30, 2025)
  • $542.9M — Gross Profit (Increased by 15.43% for the nine months ended September 30, 2025)
  • $412.39M — Total Operating Expenses (Increased by 17.41% for the nine months ended September 30, 2025)
  • $1.49 — Diluted EPS (Decreased from $1.57 for the nine months ended September 30, 2025)
  • $392.46M — Cash and Cash Equivalents (Increased from $376.72 million at December 31, 2024)
  • $2.63B — Total Assets (Increased by 8.78% from $2.42 billion at December 31, 2024)
  • 59,290,248 — Shares Outstanding (As of October 28, 2025)

Key Players & Entities

  • MERIT MEDICAL SYSTEMS INC (company) — registrant
  • Biolife (company) — acquisition target
  • NASDAQ Global Select Market (regulator) — stock exchange
  • FASB (regulator) — Financial Accounting Standards Board
  • SEC (regulator) — Securities and Exchange Commission
  • Boston Scientific (company) — competitor
  • Medtronic (company) — competitor

FAQ

What were Merit Medical Systems' net sales for the nine months ended September 30, 2025?

Merit Medical Systems reported net sales of $1,121,970 thousand for the nine months ended September 30, 2025, an increase from $1,001,356 thousand in the same period of 2024.

How did Merit Medical Systems' net income change for the nine months ended September 30, 2025?

Net income for Merit Medical Systems decreased to $90,483 thousand for the nine months ended September 30, 2025, down from $92,410 thousand in the prior year period.

What was the total operating expense for Merit Medical Systems in the nine months ended September 30, 2025?

Total operating expenses for Merit Medical Systems were $412,393 thousand for the nine months ended September 30, 2025, an increase from $351,221 thousand in the same period of 2024.

What was Merit Medical Systems' diluted earnings per common share for the nine months ended September 30, 2025?

Merit Medical Systems' diluted earnings per common share was $1.49 for the nine months ended September 30, 2025, compared to $1.57 in the prior year period.

What was the cash and cash equivalents balance for Merit Medical Systems as of September 30, 2025?

As of September 30, 2025, Merit Medical Systems had cash and cash equivalents of $392,457 thousand, up from $376,715 thousand at December 31, 2024.

Did Merit Medical Systems make any significant acquisitions during the period?

Yes, Merit Medical Systems entered into an Agreement and Plan of Merger with Biolife on May 16, 2025, indicating a significant acquisition during the period.

What are the key risks highlighted in Merit Medical Systems' 10-Q?

The 10-Q indicates a risk related to the increase in total operating expenses by 17.41% to $412,393 thousand, which outpaced net sales growth and contributed to a slight decrease in net income.

How much did Merit Medical Systems spend on capital expenditures for property and equipment?

Merit Medical Systems spent $57,252 thousand on capital expenditures for property and equipment for the nine months ended September 30, 2025, compared to $31,668 thousand in the prior year.

What was the change in Merit Medical Systems' total stockholders' equity?

Total stockholders' equity for Merit Medical Systems increased to $1,529,408 thousand as of September 30, 2025, from $1,379,359 thousand at December 31, 2024.

What is the primary business of Merit Medical Systems?

Merit Medical Systems designs, develops, manufactures, and markets medical products for interventional, diagnostic, and therapeutic procedures, operating in cardiovascular and endoscopy segments.

Risk Factors

  • Supply Chain Disruptions [medium — operational]: The company relies on a global supply chain for raw materials and components. Disruptions due to geopolitical events, natural disasters, or supplier issues could impact production and lead to increased costs, as seen with the general trend of rising inventory costs.
  • Healthcare Regulatory Changes [high — regulatory]: Changes in healthcare regulations, reimbursement policies, or approval processes by bodies like the FDA can significantly affect product demand and market access. The company operates in a highly regulated industry where compliance is paramount.
  • Competition and Pricing Pressure [medium — market]: The medical device market is competitive, with established players and emerging companies. Intense competition can lead to pricing pressures, impacting gross margins. The company's gross profit increased by 15.43%, but maintaining this growth amidst competition is a key challenge.
  • Integration of Acquisitions [medium — financial]: The acquisition of Biolife presents integration risks. Failure to successfully integrate the acquired business, achieve expected synergies, or manage associated costs could negatively impact financial performance and dilute shareholder value.
  • Product Development and Innovation [medium — operational]: Continued investment in research and development is crucial for maintaining a competitive edge. A failure to innovate or bring new products to market successfully, despite a 13.71% increase in R&D expenses, could lead to market share erosion.

Industry Context

The medical device industry is characterized by rapid technological advancements, stringent regulatory oversight, and intense competition. Companies like Merit Medical Systems Inc. operate in specialized niches, focusing on areas such as cardiology, radiology, and endoscopy. Key trends include the increasing demand for minimally invasive procedures, the growing importance of data analytics and connected devices, and consolidation through mergers and acquisitions.

Regulatory Implications

Merit Medical Systems Inc. operates within a highly regulated environment, subject to oversight from bodies like the FDA in the United States and similar agencies globally. Compliance with manufacturing standards (e.g., Quality System Regulation), product approval processes, and post-market surveillance is critical. Changes in healthcare policy, reimbursement rates, and international trade regulations can also pose significant risks.

What Investors Should Do

  1. Monitor integration of Biolife acquisition
  2. Analyze operating expense growth
  3. Evaluate R&D investment effectiveness
  4. Assess gross margin trends

Key Dates

  • 2025-09-30: Nine months ended September 30, 2025 financial results reported — Indicates continued revenue growth but a slight decrease in net income, highlighting increased operating expenses.
  • 2025-05-16: Acquisition of Biolife completed — Represents a strategic expansion effort, the full financial impact of which will be monitored in future filings.
  • 2025-10-28: Shares Outstanding reported as 59,290,248 — An increase in shares outstanding can impact EPS calculations and shareholder dilution.
  • 2025-12-31: Year-end 2024 financial position reported — Provides a baseline for comparison of 2025 performance, showing growth in assets and cash.

Glossary

Developed technology — net of accumulated amortization
Represents the cost of internally developed technology that has been expensed over its useful life. The net amount reflects the remaining value after accounting for this amortization. (An increase in this asset category, alongside goodwill, suggests significant investment in intellectual property and potentially reflects the impact of acquisitions like Biolife.)
Goodwill
An intangible asset representing the excess of the purchase price of an acquired company over the fair value of its identifiable net assets. It often reflects brand reputation, customer relationships, and other unquantifiable assets. (The substantial increase in goodwill indicates significant acquisition activity, with the Biolife acquisition likely contributing to this growth.)
Weighted average diluted shares outstanding
The total number of a company's common shares outstanding over a period, adjusted to include the dilutive effect of all potential common shares (such as stock options and convertible securities). (An increase in this metric, from 59.29 million to 60.60 million, contributed to the decrease in diluted EPS despite a slight drop in net income.)
Right-of-use operating lease assets
Assets recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (The increase in these assets, from $65.5M to $88.5M, suggests the company has entered into new operating leases, potentially for facilities or equipment, possibly related to expansion or the Biolife acquisition.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Merit Medical Systems Inc. has demonstrated robust top-line growth with net sales increasing by 12.05%. However, this growth was accompanied by a significant 17.41% rise in operating expenses, leading to a slight 2.08% decrease in net income and a dip in diluted EPS from $1.57 to $1.49. The company's balance sheet shows expansion in total assets by 8.78% and a healthy increase in cash and cash equivalents, partly supported by strategic investments in property and equipment and intangible assets, likely reflecting the recent acquisition of Biolife.

Filing Stats: 4,274 words · 17 min read · ~14 pages · Grade level 18.5 · Accepted 2025-10-30 16:12:21

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Consolidated Balance Sheets 3 Consolidated Statements of Income 5 Consolidated Statements of Comprehensive Income 6 Consolidated Statements of Stockholders' Equity 7 Consolidated Statements of Cash Flows 9 Condensed Notes to Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 43 PART II. OTHER INFORMATION 44 Item 1.

Legal Proceedings

Legal Proceedings 44 Item 1A.

Risk Factors

Risk Factors 44 Item 5. Other information 45 Item 6. Exhibits 46

SIGNATURES

SIGNATURES 47 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands) September 30, December 31, ASSETS 2025 2024 (unaudited) Current assets: Cash and cash equivalents $ 392,457 $ 376,715 Trade receivables — net of allowance for credit losses — 2025 — $ 10,113 and 2024 — $ 9,729 210,292 190,243 Other receivables 19,062 16,588 Inventories 326,550 306,063 Prepaid expenses and other current assets 31,369 28,544 Prepaid income taxes 3,651 3,286 Income tax refund receivables 2,152 2,335 Total current assets 985,533 923,774 Property and equipment: Land and land improvements 30,457 25,846 Buildings 198,563 192,296 Manufacturing equipment 357,135 340,864 Furniture and fixtures 64,115 61,321 Leasehold improvements 62,067 58,770 Construction-in-progress 83,417 58,673 Total property and equipment 795,754 737,770 Less accumulated depreciation ( 377,750 ) ( 351,605 ) Property and equipment — net 418,004 386,165 Other assets: Intangible assets: Developed technology — net of accumulated amortization — 2025 — $ 433,630 and 2024 — $ 377,993 468,819 431,766 Other — net of accumulated amortization — 2025 — $ 93,600 and 2024 — $ 85,343 69,581 66,499 Goodwill 507,427 463,511 Deferred income tax assets 16,284 16,044 Right-of-use operating lease assets 88,496 65,508 Other assets 76,854 65,336 Total other assets 1,227,461 1,108,664 Total assets $ 2,630,998 $ 2,418,603 See condensed notes to consolidated financial statements. (continued) 3 Table of Contents MERIT MEDICAL SYSTEMS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands) September 30, December 31, LIABILITIES AND STOCKHOLDERS' EQUITY 2025 2024 (unaudited) Current liabilities: Trade payables $ 64,746 $ 68,502 Accrued expenses 147,377 134,077 Short-term operating lease liabilities 10,612

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.